| Co-Investigator(Kenkyū-buntansha) |
IRIE Atsushi KUMAMOTO UNIVERSITY, GRAD.SCHL.MED.SCIENCES, RES.ASSOCIATE, 大学院・医学薬学研究部, 助手 (30250343)
SENJU Satoru KUMAMOTO UNIVERSITY, GRAD.SCHL.MED.SCIENCES, ASSOCIATE PROFESSOR, 大学院・医学薬学研究部, 助教授 (50274709)
|
|---|
| Research Abstract |
Presentation of antigenic peptides by antigen presenting cells and consequent stimulation of CD4^+ T cells is crucial in the regulation of immune response. In this research project, we studied on the recognition of antigenic peptide by T cell receptor (TCR) and signal transduction pathway in CD4^+ T cells stimulated with altered peptide ligands (APL). In addition, we established a method for ES cell-based genetic engineering of dendritic cells (DC). The following results were obtained.
1)We developed an experimental system to dentify diverse T-cell epitopes from T-cell epitope-expression library, using an epitope presenting vector based on CLIP-substituted invariant chain. Using the libraries in which randomized amino acid residues were narrowed down into three successive ones, we characterized the degeneracy in the epitopes of the GAD65-reactive Th-cell clones derived from IDDM patients, and identified several microbe-derived antigens to which the Th-cell clones cross-reacted.
2)We foun
… More
d that a human CD4^+ T cell clone showed full proliferation in response to over-expressed partially agonistic peptide/HLA-DR4 complex. However, a protein tyrosine kinase ZAP-70, which is believed to be essential for TCR-mediated T cell activation, was not tyrosine-phosphorylated and activated. Instead, we found that other kinases B-Raf and PKCm were activated in the T cells, suggesting the presence of new signaling pathways leading to full T cell proliferation that is independent of ZAP-70 activation.
3)We established a method to generate mouse ES cell-derived DC (ES-DC). Genetic modification of ES-DC can be done by transfection of ES cells and subsequent differentiation to DC. OVA antigen-specific cytotoxic T lymphocytes were efficiently primed in vivo by injecting mice with ES-DCs introduced with an OVA-expression vector. Double-transfectant ES-DC expressing a chemokine along with OVA provided potent protection from OVA-expressing tumor cells. In addition, we demonstrated prevention of experimental autoimmune encephalomyelitis by treatment with genetically modified ES-DC. Less
|
